OncLive SOSS

Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 10

Additional Key Takeaways of ASCO 2024 Data in mCR

August 1, 2024

John Marshall, MD, Al B. Benson III, MD, FACP, FACCC, FASCO , Kristen Ciombor, MD, MSCI, Stacey A. Cohen, MD, Marwan Fakih, MD

The panel of leading oncologists summarize crucial updates and key insights on colorectal cancer from the ASCO 2024 conference.

Video Player is loading.

Current Time 0:00

Duration 5:12

Loaded: 0%

Stream Type LIVE

Remaining Time 5:12

EP. 1: Overview of Molecular Testing and Barriers in mCRC

EP. 2: Clinical Considerations for 2L Treatment Sequencing in mCRC

EP. 3: Novel Combination Regimens for 2L mCRC: Insights from ASCO 202

EP. 4: Exploring Toxicities for Second Line Treatments in mCRC

EP. 5: Existing Challenges for Patients Receiving 3L+ Therapies in mCRC

EP. 6: Factors Driving 3L Therapeutic Selection for mCRC

EP. 7: Exploring Data Outcomes From the SUNLIGHT Trial

EP. 8: Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies

EP. 9: Examining the Evolving 3L Treatment Landscape for mCRC

EP. 10: Additional Key Takeaways of ASCO 2024 Data in mCR

EP. 11: Future Outlooks in the Treatment of Metastatic Colorectal Cancer

Can each of you share any noteworthy key takeaways or additional data updates on mCRC treatment discussed at ASCO 2024? (if time permits)

x